| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 26 | 2022 | 529 | 2.950 |
Why?
|
| Lipoproteins, LDL | 18 | 2022 | 343 | 1.510 |
Why?
|
| Lipoproteins | 15 | 2022 | 161 | 1.140 |
Why?
|
| Diabetic Nephropathies | 7 | 2022 | 161 | 1.100 |
Why?
|
| Diabetic Angiopathies | 10 | 2019 | 203 | 0.990 |
Why?
|
| Lipoproteins, HDL | 5 | 2016 | 113 | 0.920 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 7 | 2017 | 58 | 0.830 |
Why?
|
| Lysophospholipids | 2 | 2016 | 209 | 0.830 |
Why?
|
| Sphingosine | 3 | 2016 | 315 | 0.810 |
Why?
|
| Ceramides | 6 | 2020 | 578 | 0.780 |
Why?
|
| Sphingolipids | 7 | 2022 | 337 | 0.700 |
Why?
|
| Receptors, Lysosphingolipid | 2 | 2016 | 63 | 0.640 |
Why?
|
| Adipocytes | 4 | 2013 | 88 | 0.620 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2016 | 18 | 0.570 |
Why?
|
| Biomarkers | 9 | 2019 | 1593 | 0.560 |
Why?
|
| Carotid Intima-Media Thickness | 5 | 2018 | 54 | 0.560 |
Why?
|
| Albuminuria | 8 | 2019 | 171 | 0.550 |
Why?
|
| Apolipoproteins | 4 | 2019 | 51 | 0.540 |
Why?
|
| Antigen-Antibody Complex | 3 | 2011 | 175 | 0.510 |
Why?
|
| Apolipoproteins C | 2 | 2005 | 15 | 0.500 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2022 | 1085 | 0.490 |
Why?
|
| Diabetes Complications | 4 | 2019 | 249 | 0.460 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 301 | 0.440 |
Why?
|
| Diabetic Retinopathy | 4 | 2014 | 110 | 0.440 |
Why?
|
| Endothelium, Vascular | 5 | 2015 | 371 | 0.420 |
Why?
|
| E-Selectin | 5 | 2017 | 44 | 0.410 |
Why?
|
| Disease Progression | 6 | 2019 | 1038 | 0.410 |
Why?
|
| Lipoproteins, HDL2 | 1 | 2010 | 4 | 0.360 |
Why?
|
| Lipoproteins, HDL3 | 1 | 2010 | 4 | 0.360 |
Why?
|
| Magnetic Resonance Spectroscopy | 8 | 2015 | 346 | 0.350 |
Why?
|
| Diabetic Neuropathies | 2 | 2021 | 33 | 0.330 |
Why?
|
| Adult | 33 | 2019 | 21403 | 0.330 |
Why?
|
| Inflammation | 8 | 2017 | 1030 | 0.330 |
Why?
|
| Humans | 61 | 2022 | 68618 | 0.330 |
Why?
|
| Adiponectin | 7 | 2013 | 52 | 0.310 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 940 | 0.300 |
Why?
|
| Female | 41 | 2019 | 38074 | 0.290 |
Why?
|
| Macrophages, Peritoneal | 3 | 2013 | 67 | 0.290 |
Why?
|
| Male | 39 | 2019 | 37321 | 0.290 |
Why?
|
| Nerve Growth Factors | 2 | 2019 | 75 | 0.280 |
Why?
|
| Cholesterol | 10 | 2017 | 331 | 0.280 |
Why?
|
| Lipoproteins, VLDL | 3 | 2004 | 32 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2017 | 27 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2017 | 27 | 0.260 |
Why?
|
| Eye Proteins | 2 | 2019 | 160 | 0.260 |
Why?
|
| Cohort Studies | 11 | 2014 | 2358 | 0.260 |
Why?
|
| Fibrinogen | 2 | 2017 | 87 | 0.250 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2016 | 59 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 161 | 0.250 |
Why?
|
| Lipid Metabolism | 6 | 2020 | 186 | 0.250 |
Why?
|
| Serpins | 2 | 2019 | 205 | 0.250 |
Why?
|
| Aorta | 3 | 2016 | 316 | 0.240 |
Why?
|
| Dyslipidemias | 3 | 2015 | 98 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2003 | 50 | 0.220 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.210 |
Why?
|
| C-Reactive Protein | 6 | 2017 | 180 | 0.210 |
Why?
|
| Kidney | 4 | 2022 | 945 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 296 | 0.210 |
Why?
|
| Spleen | 2 | 2013 | 301 | 0.210 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 244 | 0.200 |
Why?
|
| Glomerular Mesangium | 3 | 2011 | 53 | 0.200 |
Why?
|
| Cytokines | 4 | 2014 | 866 | 0.200 |
Why?
|
| Metabolic Syndrome | 3 | 2013 | 191 | 0.200 |
Why?
|
| Atherosclerosis | 3 | 2015 | 204 | 0.200 |
Why?
|
| Receptors, Adiponectin | 2 | 2013 | 10 | 0.190 |
Why?
|
| Sphingomyelins | 3 | 2016 | 106 | 0.180 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2005 | 146 | 0.180 |
Why?
|
| Aryldialkylphosphatase | 2 | 2010 | 11 | 0.180 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.180 |
Why?
|
| Triglycerides | 7 | 2017 | 184 | 0.170 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2022 | 139 | 0.170 |
Why?
|
| Lipids | 6 | 2014 | 298 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 118 | 0.160 |
Why?
|
| 3T3-L1 Cells | 4 | 2013 | 30 | 0.160 |
Why?
|
| Collagen Type IV | 2 | 2011 | 28 | 0.160 |
Why?
|
| Podocytes | 1 | 2020 | 113 | 0.160 |
Why?
|
| Transcriptome | 1 | 2020 | 164 | 0.160 |
Why?
|
| Hospital Costs | 2 | 2016 | 117 | 0.160 |
Why?
|
| Animals | 17 | 2016 | 20881 | 0.160 |
Why?
|
| Biological Transport | 2 | 2016 | 210 | 0.160 |
Why?
|
| Carrier Proteins | 4 | 2015 | 597 | 0.150 |
Why?
|
| Insulin Resistance | 3 | 2005 | 241 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2020 | 2689 | 0.150 |
Why?
|
| Cross-Sectional Studies | 8 | 2018 | 2279 | 0.150 |
Why?
|
| Cells, Cultured | 9 | 2013 | 2673 | 0.150 |
Why?
|
| Pre-Eclampsia | 2 | 2009 | 202 | 0.150 |
Why?
|
| Particle Size | 2 | 2010 | 201 | 0.140 |
Why?
|
| Insulin | 5 | 2015 | 619 | 0.140 |
Why?
|
| Oxidative Stress | 4 | 2010 | 718 | 0.140 |
Why?
|
| Financial Statements | 1 | 2016 | 1 | 0.140 |
Why?
|
| Organ Culture Techniques | 1 | 2016 | 122 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 3259 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 34 | 0.130 |
Why?
|
| Economics, Hospital | 1 | 2016 | 15 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 931 | 0.130 |
Why?
|
| Risk Factors | 9 | 2015 | 5731 | 0.130 |
Why?
|
| Hepatectomy | 1 | 2016 | 58 | 0.130 |
Why?
|
| Mice | 10 | 2015 | 8474 | 0.130 |
Why?
|
| Glycosylation | 5 | 2019 | 185 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2016 | 326 | 0.130 |
Why?
|
| Macrophages | 2 | 2010 | 647 | 0.130 |
Why?
|
| Prekallikrein | 1 | 2015 | 66 | 0.130 |
Why?
|
| Young Adult | 9 | 2019 | 5717 | 0.130 |
Why?
|
| Immediate-Early Proteins | 2 | 2005 | 63 | 0.130 |
Why?
|
| Apolipoprotein C-III | 2 | 2005 | 12 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2017 | 307 | 0.120 |
Why?
|
| Middle Aged | 13 | 2019 | 21147 | 0.120 |
Why?
|
| Genotype | 3 | 2009 | 786 | 0.120 |
Why?
|
| Homocysteine | 1 | 2014 | 28 | 0.120 |
Why?
|
| Robotics | 1 | 2014 | 56 | 0.120 |
Why?
|
| Sitosterols | 2 | 2004 | 8 | 0.120 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2013 | 85 | 0.120 |
Why?
|
| Calcium | 2 | 2016 | 929 | 0.110 |
Why?
|
| Rats | 5 | 2016 | 5300 | 0.110 |
Why?
|
| DNA Primers | 2 | 2004 | 302 | 0.110 |
Why?
|
| Adolescent | 8 | 2019 | 8912 | 0.110 |
Why?
|
| Regression Analysis | 4 | 2018 | 737 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 74 | 0.110 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2009 | 58 | 0.110 |
Why?
|
| Foam Cells | 2 | 2013 | 26 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2010 | 295 | 0.100 |
Why?
|
| Blood Glucose | 5 | 2013 | 631 | 0.100 |
Why?
|
| Fibrinolysis | 2 | 2017 | 55 | 0.100 |
Why?
|
| Osmolar Concentration | 2 | 2010 | 134 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 213 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 434 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 6 | 2015 | 2791 | 0.100 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 206 | 0.090 |
Why?
|
| Mesangial Cells | 1 | 2011 | 37 | 0.090 |
Why?
|
| Veterans | 2 | 2019 | 904 | 0.090 |
Why?
|
| Oxidation-Reduction | 4 | 2008 | 567 | 0.090 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 43 | 0.090 |
Why?
|
| Receptors, IgG | 1 | 2011 | 94 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2019 | 3705 | 0.090 |
Why?
|
| Apolipoprotein A-I | 2 | 2008 | 29 | 0.090 |
Why?
|
| Interleukin-6 | 3 | 2017 | 330 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 381 | 0.080 |
Why?
|
| Cell Line | 4 | 2020 | 1752 | 0.080 |
Why?
|
| Prenatal Care | 1 | 2009 | 117 | 0.080 |
Why?
|
| Premature Birth | 1 | 2010 | 150 | 0.080 |
Why?
|
| Methionine | 1 | 2008 | 36 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 150 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 147 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 240 | 0.080 |
Why?
|
| Cholesterol, HDL | 3 | 2020 | 112 | 0.080 |
Why?
|
| Lipid Peroxidation | 2 | 2005 | 94 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 710 | 0.070 |
Why?
|
| Glycation End Products, Advanced | 2 | 2005 | 125 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2017 | 45 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 286 | 0.070 |
Why?
|
| Mutation | 2 | 2004 | 1213 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 1465 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 2 | 2005 | 384 | 0.070 |
Why?
|
| Blood Coagulation | 2 | 2017 | 123 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 274 | 0.070 |
Why?
|
| Base Sequence | 2 | 2008 | 1015 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2011 | 250 | 0.060 |
Why?
|
| Phagocytes | 1 | 2005 | 15 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1851 | 0.060 |
Why?
|
| Florida | 2 | 2016 | 221 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 77 | 0.060 |
Why?
|
| Adipose Tissue | 3 | 2013 | 221 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 72 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2005 | 104 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 56 | 0.060 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 73 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1033 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 90 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2003 | 48 | 0.060 |
Why?
|
| Rats, Inbred SHR | 1 | 2003 | 95 | 0.060 |
Why?
|
| Guanine | 1 | 2003 | 21 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 504 | 0.060 |
Why?
|
| Adenine | 1 | 2003 | 46 | 0.050 |
Why?
|
| Iron | 1 | 2005 | 197 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 188 | 0.050 |
Why?
|
| Personal Autonomy | 1 | 2002 | 22 | 0.050 |
Why?
|
| Nurse-Patient Relations | 1 | 2002 | 34 | 0.050 |
Why?
|
| Apolipoproteins M | 1 | 2022 | 5 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2002 | 40 | 0.050 |
Why?
|
| Breast Diseases | 1 | 2002 | 40 | 0.050 |
Why?
|
| Glucose | 3 | 2011 | 307 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2005 | 384 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2003 | 220 | 0.050 |
Why?
|
| Antioxidants | 1 | 2004 | 304 | 0.050 |
Why?
|
| Home Care Services | 1 | 2002 | 84 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2013 | 7 | 0.050 |
Why?
|
| Lactosylceramides | 1 | 2022 | 27 | 0.050 |
Why?
|
| Schwann Cells | 1 | 2021 | 33 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2002 | 85 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 59 | 0.050 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2021 | 74 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2010 | 1553 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 786 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2021 | 145 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2015 | 867 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 1753 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2002 | 153 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2020 | 1200 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 627 | 0.040 |
Why?
|
| Phenylacetates | 2 | 2010 | 18 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 223 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2020 | 54 | 0.040 |
Why?
|
| Focal Adhesions | 1 | 2020 | 25 | 0.040 |
Why?
|
| Pregnancy | 3 | 2010 | 2334 | 0.040 |
Why?
|
| Vitamin E | 1 | 1999 | 55 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 615 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 772 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 1999 | 74 | 0.040 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 1998 | 2 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2002 | 329 | 0.040 |
Why?
|
| Muscle, Skeletal | 2 | 2013 | 396 | 0.040 |
Why?
|
| Cholesterol, LDL | 3 | 2003 | 161 | 0.040 |
Why?
|
| Heterozygote | 1 | 1998 | 174 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1046 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 52 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2016 | 7277 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2016 | 14 | 0.030 |
Why?
|
| Liver | 2 | 2013 | 1118 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 39 | 0.030 |
Why?
|
| Hospital Units | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 18 | 0.030 |
Why?
|
| Glycosphingolipids | 1 | 2016 | 51 | 0.030 |
Why?
|
| Cysteine | 1 | 2016 | 112 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 131 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2008 | 120 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2015 | 1451 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2013 | 1034 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2005 | 76 | 0.030 |
Why?
|
| src-Family Kinases | 2 | 2008 | 91 | 0.030 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Role | 1 | 2014 | 25 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Aged | 5 | 2014 | 14862 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 1851 | 0.030 |
Why?
|
| Molecular Weight | 2 | 2006 | 358 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 521 | 0.030 |
Why?
|
| Phytosterols | 2 | 2004 | 8 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1993 | 9 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 502 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2014 | 108 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 17 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2008 | 791 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 622 | 0.030 |
Why?
|
| Metformin | 1 | 2013 | 63 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 77 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 36 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1641 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 1293 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2013 | 97 | 0.030 |
Why?
|
| Cholesterol Esters | 2 | 2005 | 26 | 0.030 |
Why?
|
| Hypertension | 2 | 2014 | 1535 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 1342 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.020 |
Why?
|
| Proteins | 2 | 2009 | 474 | 0.020 |
Why?
|
| Arteriosclerosis | 2 | 2005 | 137 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 167 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 4655 | 0.020 |
Why?
|
| Paraoxon | 1 | 2010 | 4 | 0.020 |
Why?
|
| Endosomes | 1 | 2010 | 45 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 254 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2010 | 51 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2010 | 32 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2010 | 75 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 63 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1426 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 1996 | 694 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 171 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 492 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 489 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2010 | 251 | 0.020 |
Why?
|
| Lysosomes | 1 | 2010 | 136 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 280 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Heparin | 1 | 2010 | 205 | 0.020 |
Why?
|
| Models, Biological | 2 | 2008 | 981 | 0.020 |
Why?
|
| PubMed | 1 | 2009 | 21 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 312 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 91 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 597 | 0.020 |
Why?
|
| Plasmids | 1 | 2010 | 258 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 73 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 389 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1619 | 0.020 |
Why?
|
| Kinetics | 2 | 2002 | 1047 | 0.020 |
Why?
|
| Tunica Media | 1 | 2008 | 33 | 0.020 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2008 | 59 | 0.020 |
Why?
|
| Lentivirus | 1 | 2008 | 35 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 246 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 331 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 110 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2007 | 0.020 |
Why?
|
| ras Proteins | 1 | 2008 | 102 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 266 | 0.020 |
Why?
|
| Aging | 1 | 1993 | 911 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 541 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 247 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2003 | 2083 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 284 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 742 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 8 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 1452 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 31 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 947 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1083 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2005 | 6 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 13 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 626 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2005 | 34 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 18 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2005 | 30 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2005 | 51 | 0.020 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2005 | 54 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2005 | 94 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 448 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2005 | 95 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2005 | 126 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 2004 | 24 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2005 | 175 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 2093 | 0.010 |
Why?
|
| Bile Acids and Salts | 1 | 2004 | 19 | 0.010 |
Why?
|
| Bile | 1 | 2004 | 35 | 0.010 |
Why?
|
| Lipoproteins, IDL | 1 | 2003 | 8 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 237 | 0.010 |
Why?
|
| Intestines | 1 | 2004 | 114 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2003 | 17 | 0.010 |
Why?
|
| Body Constitution | 1 | 2003 | 24 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 243 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 303 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2003 | 112 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 164 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 274 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2003 | 371 | 0.010 |
Why?
|
| South Carolina | 2 | 2003 | 2752 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 770 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2003 | 158 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 700 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7367 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 753 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 82 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1692 | 0.010 |
Why?
|
| Nitrites | 1 | 1999 | 53 | 0.010 |
Why?
|
| Cell Count | 1 | 1999 | 248 | 0.010 |
Why?
|
| Capillaries | 1 | 1999 | 105 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1664 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1999 | 304 | 0.010 |
Why?
|
| Exons | 1 | 1998 | 122 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 475 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 159 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 1999 | 122 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 208 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1998 | 420 | 0.010 |
Why?
|
| Immune System | 1 | 1996 | 63 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 1996 | 87 | 0.010 |
Why?
|
| Child | 1 | 2003 | 6405 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 546 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 507 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1993 | 4848 | 0.000 |
Why?
|